Development of a Green and Sustainable Manufacturing Process for Gefapixant Citrate (MK-7264). Part 6: Development of an Improved Commercial Salt Formation Process
- 23 October 2020
- journal article
- research article
- Published by American Chemical Society (ACS) in Organic Process Research & Development
- Vol. 24 (11) , 2498-2504
Abstract
No abstract availableKeywords
This publication has 9 references indexed in Scilit:
- Development of a Green and Sustainable Manufacturing Process for Gefapixant Citrate (MK-7264). Part 5: Completion of the API Free Base via a Direct Chlorosulfonylation ProcessOrganic Process Research & Development, 2020
- Update on novel purinergic P2X3 and P2X2/3 receptor antagonists and their potential therapeutic applicationsExpert Opinion on Therapeutic Patents, 2019
- ICH Q11: development and manufacture of drug substances–chemical and biotechnological/biological entitiesGenerics and Biosimilars Initiative Journal, 2012
- Continuous Crystallization of Aliskiren HemifumarateCrystal Growth & Design, 2012
- Crystal Polymorphism in Chemical Process DevelopmentAnnual Review of Chemical and Biomolecular Engineering, 2011
- Using the Right Green Yardstick: Why Process Mass Intensity Is Used in the Pharmaceutical Industry To Drive More Sustainable ProcessesOrganic Process Research & Development, 2011
- Crystallisation Design Space: Avoiding a Hydrate in a Water-Based ProcessOrganic Process Research & Development, 2008
- Water Activity-Mediated Control of Crystalline Phases of an Active Pharmaceutical IngredientOrganic Process Research & Development, 2007
- Crystallization in the pharmaceutical and bioprocessing industries2002